(Reuters) - The news confirms the German drugmaker's leadership in the multibillion-dollar race to bring a new class of oral anticoagulants to market.
Results of a large Phase III trial showed only 9.6 percent of patients given rivaroxaban experienced venous thromboembolism , or blood clots, following total knee replacement against 18.9 percent of those on Sanofi-Aventis SA's Lovenox.
Read more at Reuters.com Business News
Results of a large Phase III trial showed only 9.6 percent of patients given rivaroxaban experienced venous thromboembolism , or blood clots, following total knee replacement against 18.9 percent of those on Sanofi-Aventis SA's Lovenox.
Read more at Reuters.com Business News
No comments:
Post a Comment